Population screening for prostate cancer: An overview of available studies and meta-analysis

International Journal of Urology

Volumn 19, Issue 2, 2012, Pages 100-108

  Lumen, Nicolaas ^a   Fonteyne, Valérie ^a   de Meerleert, Gert ^a   Ost, Piet ^a   Villeirs, Geert ^a   Mottrie, Alexandre ^b   de Visschere, Pieter ^a   de Troyer, Bart ^a   Oosterlinck, Willem ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b OLV HOSPITAL   (Belgium)

Author keywords

Early diagnosis; Prostate biopsy; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

EARLY DIAGNOSIS; HUMANS; INCIDENCE; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WORLD HEALTH;

EID: 84856231941     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02912.x     Document Type: Review

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60: 277-300.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010; 46: 765-81.
3. Heidenreich A, Bellmunt J, Bolla M etal. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur. Urol. 2010; 59: 495-7.
4. Schroder FH, Carter HB, Wolters T etal. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur. Urol. 2008; 53: 468-77.
5. Djulbegovic M, Beyth RJ, Neuberger MM etal. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010; 341: c4543.
6. Ilic D, O'Connor D, Green S, Wilt TJ. Screening for prostate cancer: an updated Cochrane systematic review. BJU Int. 2011; 107: 882-91.
7. Bartsch G, Horninger W, Klocker H etal. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008; 101: 809-16.
8. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325: 740-46.
9. van Leeuwen PJ, Connolly D, Gavin A etal. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur. J. Cancer 2010; 46: 377-83.
10. Hugosson J, Carlsson S, Aus G etal. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11: 725-32.
11. Jegu J, Tretarre B, Grosclaude P etal. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Herault]. Prog. Urol. 2009; 19: 487-98.
12. Schroder FH, Hugosson J, Roobol MJ etal. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009; 360: 1320-8.
13. Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15years follow-up of a randomised controlled trial in Sweden. Eur. Urol. 2004; 46: 717-23; discussion 724.
14. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20years follow-up. BMJ 2011; 342: d1539.
15. Labrie F, Candas B, Cusan L etal. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-18.
16. Labrie F, Candas B, Dupont A etal. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91.
17. Roobol MJ, Kerkhof M, Schroder FH etal. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur. Urol. 2009; 56: 584-91.
18. Andriole GL, Crawford ED, Grubb RL III etal. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009; 360: 1310-19.
19. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur. Urol. 2007; 51: 659-64.
20. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J. Urol. 2009; 181: 1615-21; discussion 1621.
21. Bill-Axelson A, Holmberg L, Filen F etal. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J. Natl. Cancer Inst. 2008; 100: 1144-54.
22. Thompson IM, Ankerst DP, Chi C etal. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/mL or lower. JAMA 2005; 294: 66-70.
23. Thompson IM, Pauler DK, Goodman PJ etal. Prevalence of prostate cancer among men with a prostate-specific antigen level < or=4.0ng per milliliter. N. Engl. J. Med. 2004; 350: 2239-46.
24. Chun FK, de la Taille A, van Poppel H etal. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur. Urol. 2009; 56: 659-67.
25. Ahmed HU, Kirkham A, Arya M etal. Is it time to consider a role for MRI before prostate biopsy? Nat. Rev. 2009; 6: 197-206.
26. Villeirs GM, Oosterlinck W, Vanherreweghe E, De Meerleer GO. A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. Eur. J. Radiol. 2010; 73: 352-6.
27. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur. J. Radiol. 2011; 77: 340-5.
28. Villeirs GM, De Visschere PJ, Fonteyne VH, Lumen N, De Meerleer GO. Magnetic resonance imaging in diagnosis, staging and radiotherapy planning for prostate cancer. Acta Clin. Belg. 2010; 65: 371-6.
29. Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J. Natl. Cancer Inst. 2007; 99: 1296-303.
30. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101.
31. Lu-Yao GL, Albertsen PC, Moore DF etal. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202-9.
32. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. Cmaj 2007; 176: 1853-8.
33. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 2010; 28: 126-31.